Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBP15 in Healthy Adults
NCT02415439Phase 1Completed
- Sponsor
- ReveraGen BioPharma
- Start
- Jan 2015
- Primary completion
- Nov 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vamorolone in Duchenne muscular dystrophy (DMD) (13 arms), sponsored by ReveraGen BioPharma. Primary endpoints: Number of Subjects With Adverse Effects After a Single Dose of VBP15 at 4 days, Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 and 4 more. Started Jan 2015; status: completed.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02415439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415439.